A Phase Ii/Iii Randomized Double-Blind Study Of Octreotide Acetate Lar With Axitinib Versus Octreotide Acetate Lar With Placebo In Patients With Advanced G1-G2 Nets Of Non-Pancreatic Origin (Axinet Trial-Getne-1107).

Rocio Garcia-Carbonero,Marta Benavent,Paula Jiménez Fonseca,Daniel Castellano,Teresa Alonso,Alex Teule,Ana Custodio,Salvatore Tafuto,Adelaida La Casta Munoa,Francesca Spada,Carlos López-López,Toni Ibrahim,Maria Jose Villanueva Silva,Vega Iranzo,Pilar Garcia-Alfonso,Encarnación González,Enrique Grande,Guillermo Crespo,Jaume Capdevila

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 22|浏览18

暂无评分

摘要

360Background: Angiogenesis plays an important role in NET development and progression. Axitinib is a potent and selective VEGFR-1,2,3 inhibitor, with proven activity against several vascular-depen...

查看译文

关键词

octreotide,placebo,axitinib,double-blind,non-pancreatic,trial-getne

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要